China Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids

Reuters

09/26

<a href="https://laohu8.com/S/CHSYF">China Medical System Holdings Ltd</a>. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids

**China Medical System Holdings Ltd. Announces NMPA Approval to Initiate Clinical Trials for Innovative Uterine Fibroid Drug** China Medical System Holdings Ltd. $(CMS)$ announced that its self-developed innovative drug, CMS-D002 Capsules, has received official approval from the National Medical Products Administration (NMPA) of China to begin clinical trials for the treatment of uterine fibroids. The approval, granted on 25 September 2025, allows CMS to proceed with evaluating the safety and efficacy of CMS-D002, a novel small molecule GnRH receptor antagonist. The company stated that this milestone will strengthen its position in the gynecological treatment field and aims to bring differentiated medication options to patients in China. The announcement did not mention the involvement of any other organizations in this regulatory approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2570100060"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570100060\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570100060?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 19:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570100060","market":"nz","top_or_hot":-1,"title":"China Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CHSYF\">China Medical System Holdings Ltd</a>. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **China Medical System Holdings Ltd. Announces NMPA Approval to Initiate Clinical Trials for Innovative Uterine Fibroid Drug** China Medical System Holdings Ltd. <a href=\"https://laohu8.com/S/CMS\">$(CMS)$</a> announced that its self-developed innovative drug, CMS-D002 Capsules, has received official approval from the National Medical Products Administration (NMPA) of China to begin clinical trials for the treatment of uterine fibroids. The approval, granted on 25 September 2025, allows CMS to proceed with evaluating the safety and efficacy of CMS-D002, a novel small molecule GnRH receptor antagonist. The company stated that this milestone will strengthen its position in the gynecological treatment field and aims to bring differentiated medication options to patients in China. The announcement did not mention the involvement of any other organizations in this regulatory approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-26 19:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CHSYF\">China Medical System Holdings Ltd</a>. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **China Medical System Holdings Ltd. Announces NMPA Approval to Initiate Clinical Trials for Innovative Uterine Fibroid Drug** China Medical System Holdings Ltd. <a href=\"https://laohu8.com/S/CMS\">$(CMS)$</a> announced that its self-developed innovative drug, CMS-D002 Capsules, has received official approval from the National Medical Products Administration (NMPA) of China to begin clinical trials for the treatment of uterine fibroids. The approval, granted on 25 September 2025, allows CMS to proceed with evaluating the safety and efficacy of CMS-D002, a novel small molecule GnRH receptor antagonist. The company stated that this milestone will strengthen its position in the gynecological treatment field and aims to bring differentiated medication options to patients in China. The announcement did not mention the involvement of any other organizations in this regulatory approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL3xVbw6:1","article_id":"2570100060","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570100060","pubTimestamp":1758886034,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"China Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","BK1593":"医美概念股","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","00867":"康哲药业","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A"},"translate_title":"康哲药业获得NMPA批准启动创新GnRH受体拮抗剂CMS-D002治疗子宫肌瘤的临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":0.9},"content_text":"China Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids\n    \n\n        **China Medical System Holdings Ltd. Announces NMPA Approval to Initiate Clinical Trials for Innovative Uterine Fibroid Drug** China Medical System Holdings Ltd. $(CMS)$ announced that its self-developed innovative drug, CMS-D002 Capsules, has received official approval from the National Medical Products Administration (NMPA) of China to begin clinical trials for the treatment of uterine fibroids. The approval, granted on 25 September 2025, allows CMS to proceed with evaluating the safety and efficacy of CMS-D002, a novel small molecule GnRH receptor antagonist. The company stated that this milestone will strengthen its position in the gynecological treatment field and aims to bring differentiated medication options to patients in China. The announcement did not mention the involvement of any other organizations in this regulatory approval.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}